

## Special Issue

# Liquid Biopsy: Cancer Diagnostic Biomarkers of the Future

### Message from the Guest Editor

Cancer metastasis represents the culmination of tumor progression and is the main cause of death among patients with cancer. Notably, Circulating Tumor Cells (CTCs) comprise a rare and heterogeneous cell population that sheds from tumors and traverses the peripheral blood stream throughout the metastatic process. Consequently, the concept of “Liquid Biopsy” to interrogate CTCs and other blood analytes (ctDNA, exosomes, microRNAs, etc.) for their clinical application as precision medicine tools has significantly expanded in the last two decades, following the first implementation of Liquid Biopsy proving the clinical utility of CTCs as independent prognostic indicators of progression-free and overall survival of patients with metastatic cancer. These advances have resulted in novel analyses employing enrichment platforms which either capture CTCs by multiple parameters, profile CTC at the single-cell level, or identify specific CTC biomarker expression and/or gene transcripts. Collectively, CTC/Liquid Biopsy studies have opened new investigational avenues towards the detection and prognostication of cancer progression and responses to therapy.

### Guest Editor

Prof. Dr. Dario Marchetti

1. Division of Molecular Medicine, Department of Internal Medicine, The University of New Mexico Health Sciences Center, Albuquerque, NM 87120, USA
2. Department of Pathology, The University of New Mexico Health Sciences Center, Albuquerque, NM 87120, USA
3. UNM Comprehensive Cancer Center, Albuquerque, NM 87131, USA

### Deadline for manuscript submissions

31 December 2025



## Diagnostics

an Open Access Journal  
by MDPI

Impact Factor 3.3  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/si/209518](https://mdpi.com/si/209518)

*Diagnostics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[diagnostics@mdpi.com](mailto:diagnostics@mdpi.com)

[mdpi.com/journal/  
diagnostics](https://mdpi.com/journal/diagnostics)





# Diagnostics

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.3  
CiteScore 5.9  
Indexed in PubMed



[mdpi.com/journal/  
diagnostics](https://mdpi.com/journal/diagnostics)



## About the Journal

### Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Andreas Kjaer  
Department of Clinical Physiology, Nuclear Medicine & PET National  
University Hospital, Rigshospitalet, University of Copenhagen,  
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).